Becton, Dickinson and Company (BDX) is projected to announce its quarterly earnings soon, which has lead to increased financial activity surrounding the company's stocks. Several investors, including
AA Financial Advisors, Busey Bank and Mount Yale Investment Advisors have recently invested in BDX, adding to the company's positive momentum in the market.
Piper Sandler has raised the price target for BDX to
$280.00 following the company's declaration of dividends and the announcement of a massive
10,000,000 stock buyback. Despite the fact that BDX investors have experienced a loss over a
five-year period, the company has shown significant signs of growth and innovation. Their
53rd consecutive annual dividend increase is a testament to this. Additionally, BDX recently completed its
acquisition of Critical Care from Edwards Lifesciences and has been recognized among Fortune's most innovative companies. With new appointments like
Tim Patz as Worldwide President of Advanced Patient Monitoring and plans to expand BD's U.S. manufacturing of critical medical devices, BDX holds a promising long-term value. The company seems to be shifting toward high-growth areas, with further investments expected.
Becton Dickinson and BDX News Analytics from Tue, 26 Mar 2024 07:00:00 GMT to Sat, 01 Feb 2025 13:24:50 GMT -
Rating 5
- Innovation 7
- Information 5
- Rumor -2
